Overview

A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia

Status:
Completed

Trial end date:
2000-12-01

Target enrollment:

Participant gender:

Summary

The primary purpose of the study is to show that treatment with an injectable formulation of risperidone is not less effective than and has a similar safety profile to risperidone tablets in patients with chronic schizophrenia.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen Pharmaceutica N.V., Belgium

Treatments:

Risperidone